ProfileGDS5678 / 1434648_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 94% 94% 94% 94% 94% 94% 94% 94% 94% 94% 94% 94% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.2986395
GSM967853U87-EV human glioblastoma xenograft - Control 28.236394
GSM967854U87-EV human glioblastoma xenograft - Control 38.2329594
GSM967855U87-EV human glioblastoma xenograft - Control 48.4516294
GSM967856U87-EV human glioblastoma xenograft - Control 58.2234994
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.9123494
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.0414894
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.0367594
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.1354594
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.1276894
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.1082494
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.3347994
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.2509194
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.1670894